Antihistamínicos H1: revisión - Alergología e Inmunología Clínica

Núm. 5 Antihistamínicos H1: revisión 311
46. Vorperian VR, Zhou Z, Mohammad S, Hoon TJ,
Studenik C, January CT. Torsade de pointes with an
antihistamine metabolite: potassium channel blockade
with desmethylastemizole. J Am Coll Cardiol
1996; 28: 1556-1561.
47. Sale ME, Barbey JT, Woosley RL, Edwards D, Yeh
J, Thakker K, et al. The electrocardiographic
effects of cetirizine in normal subjects. Clin Pharmacol
Ther 1994; 56: 295-301.
48. Brannan MD, Reidenberg P, Radwanski E, Shneyer
L, Lin CC, Cayen MN, et al. Loratadine administered
concomitantly with erythromycin: pharmacokinetic
and electrocardiographic evaluations. Clin
Pharmacol Ther 1995; 58: 269-278.
49. Delgado LF, Pferferman A, Sole D, Naspitz CK.
Evaluation of the potential cardiotoxicity of the
antihistamines terfenadine, astemizol, loratadine,
and cetirizine in atopic children. Ann Allergy Asthma
Immunol 1998; 80: 333-337.
50. Ducic I, Ko CM, Shuba Y, Morad M. Comparative
effects of loratadine and terfenadine on cardiac K+
channels. J Cardiovasc Pharmacol 1997; 30: 42-54.
51. Lindquist M, Edwards IR. Risks of non-sedating
antihistamines. Lancet 1997; 349: 1322.
52. Lacerda AE, Roy ML, Lewis EW, Rampe D. Interactions
of the nonsedating antihistamine loratadine
with a Kv1.5-type potassium channel cloned from
human heart. Mol Pharmacol 1997; 52: 314-322.
53. Pratt CM, Hertz RP, Ellis BE, et al. Risk of developing
life-threatening ventricular arrhytmia associated
with terfenadine in comparison with over-thecounter
antihistamines, ibuprofen and clemastine.
Am J Cardiol 1994; 73: 346-352.
54. Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski
RF, Guinosso PJ, Lynch JJ. Cardiac electrophysiological
actions of the histamine H1 receptor antagonists
astemizole and terfenadine compared with
clorpheniramine and pyrilamine. Circ Res 1995;
76: 110-119.
55. Schuller DE. Adverse effects of brompheniramine
on pulmonary function in a subset of asthmatic children.
J Allergy Clin Immunol 1983; 72: 175-179.
56. American Academy of Allergy and Immunology:
The use of antihistamines in patients with asthma.
J Allergy Clin Immunol 1988; 82: 481-482.
57. Babe KS, Serafin WE. Histamina, bradicinina y sus
antagonistas. En: Goodman and Gilman. Las bases
farmacológicas de la terapéutica, 8ª ed. esp. Mexico
DF: McGraw-Hill Interamericana, 1996.
58. Barbanoj MJ, Antonijoan RM, García-Gea C, Massana
E, Jané F. Bases neurobioquímicas del efecto
central de los antihistamínicos. En: Álvarez FJ, del
Río MC. Antihistamínicos H1 y conducción de
vehículos. Barcelona: (Coord.) Masson SA, 1998.
29
59. Miranda Páez A. Tipos de antihistamínicos. Mesa
redonda "Antihistamínicos". III Reunión Conjunta
Societat Catalana d'Al-lèrgia/Alergólogos e Inmunólogos
del Sur. Barcelona, 1987.
60. Rietschel RL, Fowler JF. Contact Photodermatitis.
En: Fischer´s Contact Dermatitis. 4ª ed. Capítulo
23. Baltimore: Williams and Wilkins, 1995.
61. Rossoni G, Omini C, Folco GC, Vigano T, Brunelli
G, Berti F. Bronchodilating activity of mequitazine.
Arch Int Pharmacodyn Ther 1984; 268: 128 .
62. Gamboa PM, Oehling A. Ketotifeno. Su acción en
las enfermedades alérgicas. Barcelona: Laboratorios
Sandoz, 1988.
63. Patella V, de Crescenzo G, Marino O, Spadaro G,
Genovese A, Marone G. Oxatomide inhibits the
release of proinflammatory mediators from human
basophils and mast cells. Int Arch Allergy Immunol
1996; 111: 23-29.
64. Van Nueten JM, Xhonneux R, Janssen PAJ. Preliminary
data on antiserotonin effects of oxatomide,
a novel antiallergic compound. Arch Int Pharmacodyn
Ther 1978; 232: 217.
65. Ohmori K, Manabe H, Akuta-Ohnuma K. Inhibitory
effect of oxatomide on oxygen-radical generation
and peptide-leukotriene release from guinea-pig
eosinophils. Arzneimittelforschung 1998; 48: 43-46.
66. Noma T, Yoshizawa I, Kawano Y, Nakajima T.
Effect of oxatomide on T-cell activation and the
production of interferon-gamma in mite sensitive
asthma. Eur J Pharmacol 1998; 343: 239-247.
67. Connel JT, Perhach JL, Weiler JM, Rosenthal R,
Hamilton L, Diamond L, et al. Azelastine (AZ), a
new antiallergy agent: efficacy in ragweed hay
fever. Ann Allergy 1985; 55: 392.
68. McTavish D, Sorkin EM. Azelastine: a review of its
pharmacodynamic and pharmacokinetic properties,
and therapeutic potential. Drugs 1989; 38: 778-800.
69. Spaeth J, Schultze V, Klimek L, Lengersdorf A,
Mösges R. Azelastine reduces histamine-induced
swelling of nasal mucosa. ORL 1996; 58: 157-163.
70. Antépara I, Jáuregui I, Basomba A et al. Investigación
de la eficacia y tolerabilidad de azelastina
spray nasal 'versus' ebastina comprimidos en
pacientes con rinitis alérgica estacional. Allergol
Immunopathol 1998; 26: 1-8.
71. Dechant KL, Goa KL. Levocabastine: a review of
its pharmacological properties, and therapeutic
potential as a topical antihistamine in allergic rhinitis
and conjunctivitis. Drugs 1991; 41: 202-224.
72. Mösges R, Spaeth J, Klimek L. Eficacia y tolerabilidad
de levocabastina y azelastina en spray nasal
para el tratamiento de la rinitis alérgica. Mediators
Inflammation 1995, 4: S11-S15.